ClinicalTrials.gov ID NCT04467515Sponsor PrecirixLocal PI Rebecca Wong Conditions This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients with…
A Phase 1/ 2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)
ClinicalTrials.gov ID NCT01796171Sponsor Nordic NanovectorLocal PI Richard TsangConditions: Part A of the study was a Phase 1/2a study to assess the safety and preliminary efficacy of different treatment regimens of Betalutin with expansion at the candidate recommended Phase 2 doses.…
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)
ClinicalTrials.gov ID NCT02665065Sponsor Actinium PharmaceuticalsLocal PI Arjun Datt LawConditions SIERRA is a pivotal Phase 3 randomized controlled study of Iomab-B in Relapsed or Refractory AML patients. The SIERRA trial has a primary endpoint of durable Complete Remission (dCR) at six…